TLDR The review suggests limited treatments for common hair loss conditions, with potential for future improvements.
In the 1993 review, Arthur P. Bertolino discussed the anatomy, cycle, and common disorders of hair follicles, focusing on androgenetic alopecia (AGA), alopecia areata (AA), and telogen defluvium as the most diagnosed hair loss conditions. AGA was linked to genetics and androgens, AA to autoimmune disorders, and telogen defluvium to synchronized follicle resting phases. Diagnostic methods included patient history, physical examination, and tests like the hair pull test and biopsy. Treatment options were limited, with hair transplantation and topical 2% minoxidil for AGA, various topical and systemic treatments for AA, and no specific treatment for telogen effluvium. The paper highlighted ongoing research in hair biology, suggesting potential for future treatment improvements.
46 citations,
June 1990 in “Archives of dermatology” Combining 5% minoxidil and 0.5% anthralin can help regrow hair in some severe alopecia areata patients.
666 citations,
September 1977 in “British Journal of Dermatology” Common baldness, also known as Androgenetic Alopecia, is caused by a combination of genetic factors and hormones called androgens.
45 citations,
March 2010 in “Journal der Deutschen Dermatologischen Gesellschaft” A systematic approach is crucial for managing hair loss in women.
27 citations,
October 1999 in “Experimental and Molecular Pathology” Stump-tailed macaque best for researching hair loss causes and treatments.
34 citations,
March 2001 in “Cleveland Clinic Journal of Medicine” Manage hair shedding by identifying triggers, possibly using supplements or medications, and tracking with a health calendar.
12 citations,
May 1989 in “Postgraduate Medicine” The document concludes that hair loss is common and can be treated with medications like minoxidil or surgical options, and it significantly affects people's psychological well-being.
18 citations,
January 2016 in “Skin appendage disorders” The paper suggests improving diagnosis and treatment of telogen effluvium but does not recommend a new classification system.
